Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR

Ntzifa, Aliki; Kotsakis, Athanasios; Georgoulias, Vassilis; Lianidou, Evi

doi:10.3390/cancers13112736

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR

¹,

and

^1,*

Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

Department of Medical Oncology, General University Hospital of Larissa, 41110 Larissa, Greece

Hellenic Oncology Research Group (HORG), 11471 Athens, Greece

Author to whom correspondence should be addressed.

Academic Editor: Roberta Alfieri

Cancers 2021, 13(11), 2736; https://doi.org/10.3390/cancers13112736

Received: 5 April 2021 / Revised: 13 May 2021 / Accepted: 27 May 2021 / Published: 31 May 2021

(This article belongs to the Special Issue Current Status and Future Perspectives of ctDNA-Based Liquid Biopsy in Cancers)

View Full-Text Download PDF

Browse Figures

Citation Export

Simple Summary

Liquid biopsy is a useful tool during longitudinal monitoring of NSCLC patients and requires highly sensitive and reliable technologies for accurate detection of genomic alterations. We evaluated and used crystal digital PCR to detect and quantify EGFR mutations in plasma cfDNA and paired CTCs of NSCLC patients before treatment with osimertinib and at progression of disease.

Abstract

Circulating tumor DNA (ctDNA) analysis has clinical utility in EGFR mutant NSCLC. Circulating tumor cells (CTCs) consist a unique source of information at the cellular level. Digital PCR (dPCR) is a valuable tool for accurate and valid analysis of gene mutations in liquid biopsy analysis. In the present study we detected EGFR mutations in ctDNA and paired CTCs under osimertinib therapy at two time points using crystal dPCR and the naica^® system (Stilla Technologies). We quantified mutation allele frequencies (MAF) of EGFR mutations in 91 plasma cfDNA samples of 48 EGFR mutant NSCLC patients and in 64 matched CTC-derived genomic DNA samples, and the FDA-cleared cobas^® EGFR mutation test in 80 identical plasma samples. Direct comparison between crystal dPCR and the cobas EGFR assay revealed a high concordance for all EGFR mutations. Our comparison of crystal dPCR results in ctDNA with the corresponding primary tissue has shown a strong correlation. EGFR mutations analysis in paired CTC-derived gDNA revealed a high heterogeneity. Crystal dPCR offers the unique advantages of high analytical sensitivity, precision, and accuracy for detecting and quantifying multiple EGFR mutations in plasma cfDNA and CTCs of NSCLC patients. View Full-Text

Keywords: liquid biopsy; circulating tumor DNA (ctDNA); circulating tumor cells (CTC); crystal digital PCR; EGFR mutations; osimertinib

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 155 KiB)

Share and Cite

MDPI and ACS Style

Ntzifa, A.; Kotsakis, A.; Georgoulias, V.; Lianidou, E. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. Cancers 2021, 13, 2736. https://doi.org/10.3390/cancers13112736

AMA Style

Ntzifa A, Kotsakis A, Georgoulias V, Lianidou E. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. Cancers. 2021; 13(11):2736. https://doi.org/10.3390/cancers13112736

Chicago/Turabian Style

Ntzifa, Aliki, Athanasios Kotsakis, Vassilis Georgoulias, and Evi Lianidou. 2021. "Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR" Cancers 13, no. 11: 2736. https://doi.org/10.3390/cancers13112736

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR

Simple Summary

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI